Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients

BACKGROUND: Sipuleucel-T is an autologous cellular immunotherapy that is FDA approved for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (mCRPC). The IMPACT registry trial demonstrated a 4.1 month survival benefit, but not a consistent PSA respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Holl, Eda K., McNamara, Megan A., Healy, Patrick, Anand, Monika, Concepcion, Raoul S., Breland, Coleman D., Dumbudze, Igor, Tutrone, Ron, Shore, Neal, Armstrong, Andrew J., Harrison, Michael, Wallace, Joe A., Wu, Yuan, George, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853838/
https://www.ncbi.nlm.nih.gov/pubmed/30980027
http://dx.doi.org/10.1038/s41391-019-0144-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853838/
https://www.ncbi.nlm.nih.gov/pubmed/30980027
http://dx.doi.org/10.1038/s41391-019-0144-3

Ejemplares similares